Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb and AstraZeneca report positive dapagliflozin data

Bristol-Myers Squibb and AstraZeneca report positive dapagliflozin data

28th June 2011

Bristol-Myers Squibb and AstraZeneca have published positive results from a clinical study of dapagliflozin, their new treatment for type 2 diabetes.

The developmental drug has been evaluated in a phase III clinical trial, in which a combination of dapagliflozin and metformin was compared to a therapy option involving a common sulphonylurea treatment.

It was found that the dapagliflozin regimen was able to deliver sustained reductions of blood sugar levels among adult patients compared to those in the control group.

Dr Michael Nauck, head of the diabetes centre at Bad Lauterberg, said: "As we advance our knowledge of how SGLT2 inhibitors may work as a potential treatment … long-term data becomes critical to assess a compound's safety and its ability to sustain glycaemic control."

A European marketing authorisation application for the new drug has already been validated earlier this year.

Last week, Bristol-Myers Squibb published positive data from a phase III trial of Eliquis, the atrial fibrillation treatment it has developed alongside Pfizer.ADNFCR-8000103-ID-800601578-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.